Levitra 10-20 mg reviews start with IIEF, not a ranking
Buy, cheap, and reviews next to Levitra 10-20 mg usually mean a man wants a winner. The trial file will not crown one.
Online reviews collapse three different questions into a star. Did the 10 mg tablet work on a light stomach. Did the 20 mg tablet work after prostate surgery. Did anyone mention a QT drug. Those are not one score. The registration program used shared tools so the drugs can be compared without a podium: the IIEF erectile-function domain, scored 0-30, plus SEP2 and SEP3 from the encounter diary. Mean baseline EF in the four major Levitra trials was 11.8 - moderate-to-severe territory. That is the population the reviews should be read against, not a healthy volunteer.
A prescription 10 or 20 mg tablet that beat placebo on those tools is not a promise it will beat the other two brands in your hand. Head-to-head ranking was not the design. If you want the molecule's working note, including the holds, use the vardenafil signal page. This file stays with what the rooms actually counted.
Four rooms, 2431 men, one shared scorecard
The US label pools four major double-blind, randomized, placebo-controlled, fixed-dose, parallel, multicenter trials in 2431 men aged 20-83, mean age 57. Doses were 5, 10, and 20 mg, as needed, without regard to meals. Two rooms were a general ED population. One was diabetes. One was post-prostatectomy. Primary look was at three months. All four rooms showed clinically meaningful, statistically significant gains on EF domain, SEP2, and SEP3 versus placebo. The drug also worked across age bands and across the race groups the trials actually enrolled.
That pooled sentence is the floor, not the interesting wall. The interesting wall is how the numbers shrink when the vessels and the nerves are already damaged, and how a separate cardiac study - not an ED trial - is what isolates this INN. Keep those layers apart or you will read a diabetes SEP3 as if it were a ranking against tadalafil. It is not.
Porst's at-home file and the North American ladder
Porst's 2001 at-home trial came first. The North American fixed-dose room is the ladder most US labels still echo.
| Room | N | 10 mg signal | 20 mg signal | Placebo |
|---|---|---|---|---|
| North American EF domain | 762 | 21 | 21 | 15 |
| North American SEP2 | 762 | 75% | 80% | 52% |
| North American SEP3 | 762 | 64% | 65% | 32% |
| Diabetes EF domain | 439 | 17 | 19 | 13 |
| Diabetes SEP3 | 439 | 49% | 54% | 23% |
| Post-prostatectomy EF | 427 | 15 | 15 | 9 |
| Post-prostatectomy SEP3 | 427 | 37% | 34% | 10% |
Porst and colleagues randomized 601 men with mixed-etiology ED to placebo or 5, 10, or 20 mg for 12 weeks. Primary items were IIEF Q3 (penetration) and Q4 (maintenance). All three active doses beat placebo. Successful intercourse sat between 71 and 75% on vardenafil. On the 20 mg dose, 80% of men said erections improved on the global assessment question, against 30% on placebo. Headache, flush, and rhinitis were the usual class noise. That file answered the first ping: the tablet works at home, not only in a lab.
The major North American fixed-dose trial enrolled 762 men, mean age 57. Baseline EF sat at 13-14 across arms. At three months, EF domain was 18, 21, and 21 on 5, 10, and 20 mg against 15 on placebo. SEP2 - erection firm enough to penetrate - was 65%, 75%, and 80% against 52% placebo. SEP3 - erection held for successful intercourse - was 51%, 64%, and 65% against 32% placebo. A European room of 803 men confirmed the pattern. Gains held at six months in the North American file. Read those 10 and 20 mg columns as a ladder, not as proof that 20 is always the better night. Side effects climb too.
Diabetes and nerve-sparing prostatectomy were the hard rooms
Goldstein's diabetes trial - 439 men on the label count, type 1 or type 2, ED longer than six months, HbA1c at or under 12% - is the honest test. Diabetes chews small vessels and nerves. Every PDE5 inhibitor loses ground there. After 12 weeks, EF domain was 17 on 10 mg and 19 on 20 mg against 13 on placebo. SEP2 was 61% and 64% against 36%. SEP3 was 49% and 54% against 23%. Goldstein's GAQ line in the published paper: 57% and 72% said erections improved, against 13% on placebo. Real. Smaller than the general rooms. That honesty is the point.
The post-prostatectomy room enrolled 427 men, mean age 60, after radical prostatectomy. EF domain reached 15 on both 10 and 20 mg against 9 on placebo. SEP2 sat at 47-48% against 22%. SEP3 sat at 37% and 34% against 10%. Brock's published GAQ in 440 randomized men: 65.2% on 20 mg and 59.4% on 10 mg against 12.5% placebo, and among bilateral nerve-sparing men 71.1% and 59.7% against 11.5%. The nerve that starts the cascade has to be at least partly there. A 20 mg tablet cannot invent a signal the surgery removed. Parallel hard-room files for the siblings sit in the sildenafil trial note and the tadalafil evidence note.
The 59-man QT study is a flag, not a scare headline
Efficacy rooms do not isolate this INN. A crossover in 59 healthy men aged 45-60 does.
| Who | Levitra 10-20 mg read | Why |
|---|---|---|
| No rhythm history, no QT drug | Footnote | Small QTc change, class nitrate rule still applies |
| Congenital long QT | Avoid | Interval already long from birth |
| Quinidine or procainamide (IA) | Avoid | QT effects add |
| Amiodarone or sotalol (III) | Avoid | QT effects add |
| Other QT-prolonging drugs | Clinician call | Label says consider; do not freelance |
| Nitrate or riociguat | Closed for the class | Pressure, not QT |
Investigators gave therapeutic 10 mg film-coated vardenafil and supratherapeutic 80 mg - four times the labeled ceiling, chosen to cover the concentrations you see when a low 5 mg dose meets ritonavir 600 mg twice daily - against placebo and against moxifloxacin 400 mg. QT was read at one hour, near peak. Therapeutic and supratherapeutic vardenafil and the active control produced similar QTc stretches. The study was not built for a statistical bake-off between doses. The clinical impact of those millisecond changes is unknown, and the label says so. Unknown is not the same as none.
A later postmarketing study in 44 healthy volunteers put cleaner numbers on an add-on. Single-dose 10 mg Levitra: placebo-subtracted QTcF +5 msec (90% CI 2-8). Gatifloxacin 400 mg: +4 msec (1-7). Together: +9 msec (6-11). Additive. That is the flag. Not torsades in the average man on a 10 or 20 mg tablet. Additive stretch when another QT-active drug is already on board.
Class IA and III antiarrhythmics close the door
The label's avoid list is short and specific. Congenital QT prolongation. Class IA antiarrhythmics - quinidine, procainamide. Class III - amiodarone, sotalol. Those men should not use Levitra. Other QT-prolonging drugs are a consider, not an automatic yes. A baseline ECG and a medication list settle more arguments than a forum review. When the rhythm file is messy, I pick a different PDE5 rather than bargain a 10 mg start.
CYP3A4 sits next to that flag because inhibitors raise exposure and the 80 mg QT arm was built to cover a ritonavir-level climb. Ritonavir 600 mg twice daily with 5 mg vardenafil: 49-fold AUC, 13-fold Cmax, half-life out to 26 hours, labeled cap 2.5 mg once in 72 hours. Indinavir: 16-fold AUC, 7-fold Cmax, cap 2.5 mg daily. Ketoconazole 200 mg: 10-fold AUC, cap 5 mg. Ketoconazole 400 mg or itraconazole 400 mg: cap 2.5 mg daily. Erythromycin: 4-fold AUC, cap 5 mg. Grapefruit juice is named as a likely increaser even without a dedicated study. Dose caps are not a ranking. They are how you keep a 10-20 mg story from becoming an 80 mg exposure.
Nitrates still outrank every SEP3 gain
Every efficacy number on this page loses to one contraindication. Vardenafil plus nitrates or nitric oxide donors can drop blood pressure to a dangerous, sometimes fatal, low. The label has not set a safe interval. Riociguat, a guanylate-cyclase stimulator, is closed for the same pressure reason. A man with coronary disease is also more likely to carry both a nitrate and a QT-active antiarrhythmic. That is two independent reasons to stay off this tablet, not a puzzle to solve with a smaller dose.
Alpha-blockers are a caution, not that absolute. Both classes vasodilate. Start the PDE5 at the lowest recommended dose only after the alpha-blocker is stable. Separate the timing. Volume depletion and other antihypertensives stack the drop. Elderly men at or over 65 showed 34% higher Cmax and 52% higher AUC; a 5 mg start is worth considering. Moderate hepatic impairment (Child-Pugh B) jumped Cmax 130% and AUC 160% after 10 mg; start 5 mg, ceiling 10 mg. Severe hepatic impairment was not studied. Those are filing rules. They are not a podium.
How this desk files the 10-20 mg reviews
Elena's post from Edinburgh: Levitra 10-20 mg is an effective on-demand tablet with an unusually well-drawn safety personality. The general rooms moved IIEF and SEP the way the class moves them. The diabetes and prostatectomy rooms moved them less, which is what damaged plumbing should do. Porst, the North American ladder, Goldstein, Brock - those names are the evidence. They are not a reason to rank this tablet above sildenafil or tadalafil.
What isolates vardenafil is the QT flag on top of the class-wide nitrate ban. For most men neither blocks a fill. For a man with congenital long QT, an IA or III antiarrhythmic, or a nitrate he cannot drop, those two facts decide and point him elsewhere. Match the tablet to the heart, not to a review star. The path that put the tablet on a US shelf is in the Bayer-to-Levitra path. The night mechanics are in the fat and hour-mark file. Bring your own list to your own prescriber. This page is a teaching line.